Üks Life4me+ peamiseid eesmärke on uute HIVi- ja muude sugulisel teel levivate nakkuste juhtumite, nagu ka C-hepatiiti ja tuberkuloosi nakatumise ennetamine.

Nutirakendus aitab luua kontakti arstide ja HIV positiivsete inimeste vahel. Nutirakendus aitab mugavalt organiseerida ravimite võtmise aegu, seadistada ainult Teile arusaadavad ja personaalseid meeldetuletusi, võimaldab saada arstilt tagasisidet ning panna aega vastuvõtule või analüüsidele.

Tagasi
13 aprill 2017, 11:39
3994

Math Model Suggests HIV Vaccine Still Has Pivotal Role In Ending AIDS

Math Model Suggests HIV Vaccine Still Has Pivotal Role In Ending AIDS - pilt 1

Scientists from the Yale School of Public Health conducted a major study on the impact and cost-effectiveness of HIV vaccines. According to the results of the work published in the Proceedings of the National Academy of Sciences, even an ineffective (from 50%) vaccine combined with other methods of prevention can prevent 17 million new infections in the coming years.

The researchers, led by Alison Galvani, developed a mathematical model of the HIV epidemic progression, which showed that maintaining the status quo in treatment and diagnosis would lead to 49 million new HIV / AIDS cases in the world in 2015-2035. The use of a vaccine with a relatively low efficiency could reduce this figure down to 32 million.

According to Galvani, even if UNAIDS will achieve its ambitious goals within the 90-90-90 program framework, the additional advantage of a partially effective vaccine would be a huge help in overcoming the pandemic and saving millions of lives around the world.

However, the key problem in implementing such a plan is the fact that vaccines are put into production only with the proven effectiveness of 80-95%, while the creation of an HIV vaccines associated with some difficulties. A live HIV-based vaccine can produce more harm than good, where an inactivated virus vaccine has not shown efficacy above 39% to date.

The last major tests of the HIV vaccine were held in Thailand seven years ago. These days a placebo-controlled trial of such a vaccine is taking place in South Africa. It will be put into production if it will show the efficiency at least 50%. The first results of the study in South Africa will be known in 2020.

Autor: Liliya Ten

Jaga suhtlusvõrkudes